392 related articles for article (PubMed ID: 23050510)
21. Aetna includes medications in weight-loss strategies.
Diamond F
Manag Care; 2014 Jul; 23(7):44-5. PubMed ID: 25199370
[No Abstract] [Full Text] [Related]
22. New developments in the pharmacologic treatment of obesity.
Fantasia HC
Nurs Womens Health; 2013; 17(1):53-62. PubMed ID: 23399013
[TBL] [Abstract][Full Text] [Related]
23. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525
[No Abstract] [Full Text] [Related]
24. ACS chemical neuroscience molecule spotlight on Qnexa.
Mercer SL
ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
[TBL] [Abstract][Full Text] [Related]
25. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
Prescrire Int; 2012 Sep; 21(130):209. PubMed ID: 23016252
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of medications approved for chronic weight management.
Fujioka K
Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S7-11. PubMed ID: 25900872
[TBL] [Abstract][Full Text] [Related]
27. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
28. Lorcaserin for weight loss: insights into US Food and Drug Administration approval.
Miller LE
J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720
[No Abstract] [Full Text] [Related]
29. Drug treatment of obesity in the cardiovascular patient.
Charakida M; Tousoulis D; Finer N
Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
[TBL] [Abstract][Full Text] [Related]
30. Phentermine plus topiramate in the treatment of obesity.
Malgarini RB; Pimpinella G
Lancet; 2011 Jul; 378(9786):125-6; author reply 126-7. PubMed ID: 21742167
[No Abstract] [Full Text] [Related]
31. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
32. Phentermine and topiramate extended-release for the obesity: new kids on the block.
Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I
Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717
[TBL] [Abstract][Full Text] [Related]
33. New medications for weight loss.
Murfin M
JAAPA; 2012 Dec; 25(12):59-60. PubMed ID: 23600006
[No Abstract] [Full Text] [Related]
34. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
35. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Halpern B; Faria AM; Halpern A
Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337
[TBL] [Abstract][Full Text] [Related]
36. What cost weight loss?
Hiatt WR; Thomas A; Goldfine AB
Circulation; 2012 Mar; 125(9):1171-7. PubMed ID: 22392864
[No Abstract] [Full Text] [Related]
37. Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
[TBL] [Abstract][Full Text] [Related]
38. Obesity Pharmacotherapy.
Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
[TBL] [Abstract][Full Text] [Related]
39. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
40. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B; Mancini MC
Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
